|
시장보고서
상품코드
1463146
인플루엔자 치료제 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 인플루엔자 유형별, 치료별, 유통 채널별, 지역별, 부문별 예측(2024-2032년)Influenza Medications Market Share, Size, Trends, Industry Analysis Report, By Influenza Type (Influenza A and Influenza B); By Treatment; By Distribution Channel; By Region; Segment Forecast, 2024- 2032 |
||||||
Polaris Market Research의 최신 조사에 따르면, 세계 인플루엔자 치료제 시장 규모는 2032년까지 13억 8,621만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.
계절성 인플루엔자 유행, 전염성 호흡기 질환의 유행, 인플루엔자 관련 합병증 발병 위험이 높은 환자 증가는 시장 성장을 가속하는 주요 요인입니다. 인플루엔자 확산을 억제하기 위한 백신 접종 프로그램과 인플루엔자 조기 진단 및 치료의 중요성에 대한 인식과 같은 정부의 이니셔티브이 증가함에 따라 시장 성장을 더욱 촉진할 것으로 예상됩니다.
예를 들어, 2023년 9월 건강보호센터(Centre for Health Protection)의 보고서에 따르면, 2023년 10월에 정부 백신 접종 프로그램이 시작될 예정이며, 이에 따라 정부는 계절성 인플루엔자 예방접종을 무료로 제공합니다.
또한, 인플루엔자 치료제 분야의 연구 개발 활동이 활발해지고, 더 많은 제약회사가 바이러스의 여러 단계를 표적으로 삼아 인플루엔자을 더 효율적으로 치료할 수 있는 더 효과적인 항바이러스제를 개발하기 위해 노력하고 있는 것도 시장 성장을 더욱 촉진하고 있습니다. 예를 들어, 옥스포드 대학이 2023년 10월에 발표한 보고서에 따르면, 매년 약 290,000명에서 650,000명의 사망자를 발생시키는 인플루엔자 치료법을 연구하기 위해 RECOVERY 트레일이 확대되었습니다.
인플루엔자 확산에 대응하기 위해 보다 효과적이고 안전한 항바이러스제가 필요함에 따라 각 제약사들은 차세대 항바이러스제와 같은 혁신적인 항바이러스제를 도입하고 있습니다. 이 항바이러스제는 효능이 향상되고, 여러 인플루엔자 균주에 대해 더 넓은 활성 스펙트럼을 가지며, 부작용을 감소시켜 인플루엔자 치료제 수요에 긍정적인 영향을 미치고 있습니다.
또한, 면역 반응이나 유전적 체질 등 환자 개개인의 특성에 따라 인플루엔자 치료를 조정하는 개인 맞춤형 의료가 발전하고 있는 것도 전 세계 제품 수요를 더욱 증가시키고 있습니다. 예를 들어, 2023년 7월 인도 과학 연구소의 연구에 따르면, 피콜린산은 인플루엔자을 포함한 다양한 질병을 유발하는 바이러스를 차단할 수 있으며, 일부 바이러스성 질환을 퇴치하는 데 도움이 될 수 있다고 보고했습니다.
인플루엔자치료제 시장 보고서 하이라이트
인플루엔자 A형 인플루엔자 치료제 부문은 발병률 증가와 적절한 투약의 중요성에 대한 인식이 높아짐에 따라 높은 점유율을 차지할 것으로 예상됩니다.
오셀타미비르 인산염은 여러 균주에 대한 높은 효율성과 유효성 등의 장점으로 인해 대부분의 점유율을 차지하고 있습니다.
온라인 약국의 부상은 환자에게 편리함과 접근성 등 여러 가지 이점을 가져다 줄 수 있습니다.
북미는 인플루엔자의 유행과 새로운 제제 개발을 위한 연구개발 투자 증가로 인해 시장을 독점하고 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 인플루엔자 치료제 시장 인사이트
- 인플루엔자 치료제 시장-유통 채널 현황
- 인플루엔자 치료제 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
- PESTEL 분석
- 인플루엔자 치료제 시장 유통 채널 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 독감 유형별 세계 시장
- 주요 조사 결과
- 서론
- A형 독감
- B형 독감
제6장 치료별 세계 시장
- 주요 조사 결과
- 서론
- Baloxavir Marboxil
- Oseltamivir Phosphate
- 기타
제7장 유통 채널별 세계 시장
- 주요 조사 결과
- 서론
- 병원 약국
- 소매 약국
- 온라인 약국
- 기타
제8장 지역별 세계 시장
- 주요 조사 결과
- 서론
- 독감 치료제 시장 평가, 지역별, 2019-2032년
- 독감 치료제 시장-북미
- 북미 : 독감 치료제 시장, 독감 유형별, 2019년-2032년
- 북미 : 독감 치료제 시장, 유통 채널별, 2019년-2032년
- 북미 : 독감 치료제 시장, 치료별, 2019년-2032년
- 독감 치료제 시장-미국
- 독감 치료제 시장-캐나다
- 독감 치료제 시장-유럽
- 유럽 : 독감 치료제 시장, 독감 유형별, 2019년-2032년
- 유럽 : 독감 치료제 시장, 유통 채널별, 2019년-2032년
- 유럽 : 독감 치료제 시장, 치료별, 2019년-2032년
- 독감 치료제 시장-영국
- 독감 치료제 시장-프랑스
- 독감 치료제 시장-독일
- 독감 치료제 시장-이탈리아
- 독감 치료제 시장-스페인
- 독감 치료제 시장-네덜란드
- 독감 치료제 시장-러시아
- 독감 치료제 시장-아시아태평양
- 아시아태평양 : 독감 치료제 시장, 독감 유형별, 2019년-2032년
- 아시아태평양 : 독감 치료제 시장, 유통 채널별, 2019년-2032년
- 아시아태평양 : 독감 치료제 시장, 치료별, 2019년-2032년
- 독감 치료제 시장 - 중국
- 독감 치료제 시장 - 인도
- 독감 치료제 시장 - 말레이시아
- 독감 치료제 시장 - 일본
- 독감 치료제 시장 - 인도네시아
- 독감 치료제 시장 - 한국
- 독감 치료제 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 독감 치료제 시장, 독감 유형별, 2019년-2032년
- 중동 및 아프리카 : 독감 치료제 시장, 유통 채널별, 2019년-2032년
- 중동 및 아프리카 : 독감 치료제 시장, 치료별, 2019-2032년
- 독감 치료제 시장 - 사우디아라비아
- 독감 치료제 시장 - 아랍에미리트(UAE)
- 독감 치료제 시장 - 이스라엘
- 독감 치료제 시장 - 남아프리카
- 독감 치료제 시장 - 라틴아메리카
- 라틴아메리카 : 독감 치료제 시장, 독감 유형별, 2019년-2032년
- 라틴아메리카 : 독감 치료제 시장, 유통 채널별, 2019년-2032년
- 라틴아메리카 : 독감 치료제 시장, 치료별, 2019년-2032년
- 독감 치료제 시장 - 멕시코
- 독감 치료제 시장 - 브라질
- 독감 치료제 시장 - 아르헨티나
제9장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 파트너십/협업/계약/공개
제10장 기업 개요
- AbbVie(US)
- AstraZeneca(UK)
- Bayer AG(Germany)
- Bharat Biotech(India)
- BioCryst Pharmaceuticals(US)
- Daiichi Sankyo(Japan)
- Mylan(US)
- Novartis AG(Switzerland)
- Roche Diagnostics(Switzerland)
- Sanofi SA(France)
- Seqirus(Australia)
The global influenza medications market size is expected to reach USD 1,386.21 million by 2032, according to a new study by Polaris Market Research. The report "Influenza Medications Market Share, Size, Trends, Industry Analysis Report, By Influenza Type (Influenza A and Influenza B); By Treatment; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The proliferation of seasonal flu, greater prevalence of contagious respiratory illness, and increasing patient population who are at higher risk of developing flu-related complications, are key factors driving the market growth. Growing number of government initiatives like vaccination programs for controlling the spread of influenza and awareness regarding the importance of early diagnosis and treatment of influenza, are further anticipated to propel market growth.
For instance, according a report by the Centre for Health Protection in September 2023, the Government Vaccination Programme was launched in October 2023 under which the government continued to provide seasonal influenza vaccination for free of cost.
Furthermore, growing research & development activities in the field of influenza medications and growing number of pharmaceutical companies implementing on the development of more effective antiviral drugs that can treat influenza more efficiently through targeting different stages of viral, are further boosting the market's growth. For instance, according to a report by the University of Oxford in October 2023, the RECOVERY trail has been expanded for investigating treatments for influenza that cause deaths of approx. 290,000 to 650,000 people each year.
As the need for effective and safer antiviral drugs to combat the spread of influenza, companies are introducing innovative antiviral drugs like next-generation antiviral drugs which offer enhanced efficacy, broader spectrum of activity against the several influenza strains, and reduced side effects, which is impacting the demand for influenza medications in a positive way.
Additionally, ongoing advances in personalized medicine tailoring to influenza treatment based on individual patient characteristics like immune response and genetic make-up, further escalating the product demand globally. For instance, according to a study done by the Indian Institute of Science in July 2023, it is reported that picolinic acid has the potential to block various disease-causing viruses including influenza and it also help to fight against several viral diseases.
Influenza Medications Market Report Highlights
Influenza A segment accounted for notable share, owing to rising incidences and awareness regarding the importance of proper medications
Oseltamivir phosphate segment held the majority share, that is attributed to its advantages including higher efficiency and effectiveness against several strains
Online pharmacies segment will grow at highest pace, emergence of online pharmacy platforms offering several benefits to patients like convenience and easy accessibility
North America dominated the market, on account of prevalence of influenza and rising investments in R&D activities to develop new formulations
The key market players include Bayer, Roche Diagnostics, Novartis, Sanofi, AstraZeneca, AbbVie, BioCryst Pharmaceuticals, and Mylan
Polaris Market Research has segmented the influenza medications market report based on influenza type, treatment, distribution channel, and region:
Influenza Medications, Influenza Type Outlook (Revenue - USD Million, 2023 - 2032)
- Influenza A
- Influenza B
Influenza Medications, Treatment Outlook (Revenue - USD Million, 2023 - 2032)
- Baloxavir Marboxil
- Oseltamivir Phosphate
- Others
Influenza Medications, Distribution Channel Outlook (Revenue - USD Million, 2023 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Influenza Medications, Regional Outlook (Revenue - USD Million, 2023 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Influenza Medications Market Insights
- 4.1. Influenza Medications Market - Distribution Channel Snapshot
- 4.2. Influenza Medications Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising incidences of influenza and increasing awareness about public health
- 4.2.1.2. Increased R&D efforts and growing regulatory
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Seasonal demand and availability of alternative treatments
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Influenza Medications Market Distribution Channel Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Influenza Medications Market, by Influenza Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 5.3. Influenza A
- 5.3.1. Global Influenza Medications Market, by Influenza A, by Region, 2019-2032 (USD Million)
- 5.4. Influenza B
- 5.4.1. Global Influenza Medications Market, by Influenza B, by Region, 2019-2032 (USD Million)
6. Global Influenza Medications Market, by Treatment
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 6.3. Baloxavir Marboxil
- 6.3.1. Global Influenza Medications Market, by Baloxavir Marboxil, by Region, 2019-2032 (USD Million)
- 6.4. Oseltamivir Phosphate
- 6.4.1. Global Influenza Medications Market, by Oseltamivir Phosphate, by Region, 2019-2032 (USD Million)
- 6.5. Others
- 6.5.1. Global Influenza Medications Market, by Others, by Region, 2019-2032 (USD Million)
7. Global Influenza Medications Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 7.3. Hospitals Pharmacies
- 7.3.1. Global Influenza Medications Market, by Hospitals Pharmacies, By Region, 2019-2032 (USD Million)
- 7.4. Retail Pharmacies
- 7.4.1. Global Influenza Medications Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
- 7.5. Online Pharmacies
- 7.5.1. Global Influenza Medications Market, by Online Pharmacies, By Region, 2019-2032 (USD Million)
- 7.6. Others
- 7.6.1. Global Influenza Medications Market, by Others, By Region, 2019-2032 (USD Million)
8. Global Influenza Medications Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Influenza Medications Market Assessment, By Geography, 2019-2032 (USD Million)
- 8.3. Influenza Medications Market - North America
- 8.3.1. North America: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.3.2. North America: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.3. North America: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.3.4. Influenza Medications Market - U.S.
- 8.3.4.1. U.S.: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.3.4.2. U.S.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.4.3. U.S.: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.3.5. Influenza Medications Market - Canada
- 8.3.5.1. Canada: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.3.5.2. Canada.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.3.5.3. Canada: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.4. Influenza Medications Market - Europe
- 8.4.1. Europe: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.4.2. Europe.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.3. Europe: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.4.4. Influenza Medications Market - UK
- 8.4.4.1. UK: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.4.4.2. UK.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.4.3. UK: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.4.5. Influenza Medications Market - France
- 8.4.5.1. France: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.4.5.2. France.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.5.3. France: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.4.6. Influenza Medications Market - Germany
- 8.4.6.1. Germany: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.4.6.2. Germany.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.6.3. Germany: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.4.7. Influenza Medications Market - Italy
- 8.4.7.1. Italy: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.4.7.2. Italy.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.7.3. Italy: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.4.8. Influenza Medications Market - Spain
- 8.4.8.1. Spain: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.4.8.2. Spain.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.8.3. Spain: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.4.9. Influenza Medications Market - Netherlands
- 8.4.9.1. Netherlands: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.4.9.2. Netherlands.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.9.3. Netherlands: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.4.10. Influenza Medications Market - Russia
- 8.4.10.1. Russia: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.4.10.2. Russia.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.4.10.3. Russia: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.5. Influenza Medications Market - Asia Pacific
- 8.5.1. Asia Pacific: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.5.2. Asia Pacific.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.3. Asia Pacific: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.5.4. Influenza Medications Market - China
- 8.5.4.1. China: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.5.4.2. China.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.4.3. China: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.5.5. Influenza Medications Market - India
- 8.5.5.1. India: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.5.5.2. India.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.5.3. India: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.5.6. Influenza Medications Market - Malaysia
- 8.5.6.1. Malaysia: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.5.6.2. Malaysia.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.6.3. Malaysia: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.5.7. Influenza Medications Market - Japan
- 8.5.7.1. Japan: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.5.7.2. Japan.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.7.3. Japan: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.5.8. Influenza Medications Market - Indonesia
- 8.5.8.1. Indonesia: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.5.8.2. Indonesia.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.8.3. Indonesia: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.5.9. Influenza Medications Market - South Korea
- 8.5.9.1. South Korea: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.5.9.2. South Korea.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.5.9.3. South Korea: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.6. Influenza Medications Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.6.2. Middle East & Africa.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.3. Middle East & Africa: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.6.4. Influenza Medications Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.6.4.2. Saudi Arabia.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.4.3. Saudi Arabia: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.6.5. Influenza Medications Market - UAE
- 8.6.5.1. UAE: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.6.5.2. UAE.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.5.3. UAE: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.6.6. Influenza Medications Market - Israel
- 8.6.6.1. Israel: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.6.6.2. Israel.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.6.3. Israel: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.6.7. Influenza Medications Market - South Africa
- 8.6.7.1. South Africa: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.6.7.2. South Africa.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.6.7.3. South Africa: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.7. Influenza Medications Market - Latin America
- 8.7.1. Latin America: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.7.2. Latin America.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.3. Latin America: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.7.4. Influenza Medications Market - Mexico
- 8.7.4.1. Mexico: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.7.4.2. Mexico.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.4.3. Mexico: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.7.5. Influenza Medications Market - Brazil
- 8.7.5.1. Brazil: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.7.5.2. Brazil.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.5.3. Brazil: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
- 8.7.6. Influenza Medications Market - Argentina
- 8.7.6.1. Argentina: Influenza Medications Market, by Influenza Type, 2019-2032 (USD Million)
- 8.7.6.2. Argentina.: Influenza Medications Market, by Distribution Channel, 2019-2032 (USD Million)
- 8.7.6.3. Argentina: Influenza Medications Market, by Treatment, 2019-2032 (USD Million)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. AbbVie (US)
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. AstraZeneca (UK)
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Bayer AG (Germany)
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Bharat Biotech (India)
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. BioCryst Pharmaceuticals (US)
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Daiichi Sankyo (Japan)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Mylan (US)
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Novartis AG (Switzerland)
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Roche Diagnostics (Switzerland)
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Sanofi SA (France)
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Seqirus (Australia)
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
